Floatz logo

Jab-2485

Small Cell Lung Cancer, SCLC

Jacobio Pharmaceuticals Co., Ltd.Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

290 Active assets in the Small Cell Lung Cancer, SCLC cohort.

Asset / SponsorPhaseRating
Benmelstobart
Yayi He
Phase 4A
vx-970
National Cancer Institute (NCI)
Phase 2BBB
Adebelimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3BBB
Veliparib
Central European Society for Anticancer Drug Research
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BB

View all 50 →

Same molecule, other indications

Jab-2485 is also rated in:

triple-negative breast carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
ARID1A Gene MutationDormant
CCC
Indicative ·
48 / 100
View asset →
estrogen-receptor positive breast cancerDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →